INSM Insmed Incorporated
$117.83
Insmed Incorporated (INSM) is expected to report earnings on October 30, 2026, before the market open. The consensus earnings estimate is a loss of $0.37 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -8.1% since its last earnings release on August 6, 2026.
Insmed Beat Consensus Estimates
Thursday, August 6, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 30
Friday · 7:00 AM ET
Earnings Whisper
-
vs ($0.37)
Rev est $497.89M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$126.70
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Insmed Incorporated
Insmed Inc is a biopharmaceutical company engaged in developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. Its products candidates includes ARIKAYCE.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.